Conference Coverage

VIDEO: Real-world proof that treat-to-target works in rheumatoid arthritis


 

AT THE ACR ANNUAL MEETING

References

San Francisco – Treat-to-target should be the goal of every office visit for rheumatoid arthritis, according to a joint European and North American investigation involving more than 500 patients.

That’s because it works, explained study investigator Dr. Sofia Ramiro, a rheumatology fellow at Leiden (the Netherlands) University Medical Center.

The study confirms what has long been suspected but not exactly demonstrated before in a robust, real-world setting, she noted. The findings also suggest that some rheumatoid arthritis patients probably could be pushed harder toward remission.

In an interview at the annual meeting of the American College of Rheumatology, Dr. Ramiro explained the project and why it matters for clinical care.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

aotto@frontlinemedcom.com

Recommended Reading

Three-month time point critical in T2T
MDedge Rheumatology
Switching to rituximab more efficacious than switching anti-TNF agents
MDedge Rheumatology
High cholesterol predicts RA in women
MDedge Rheumatology
Serious infection risk rose with opioid use in rheumatoid arthritis
MDedge Rheumatology
No stone left unturned in ACR 2015 clinical sessions
MDedge Rheumatology
Shingles vaccine protection lasted 5-6 years in autoimmune disease patients
MDedge Rheumatology
Stroke risk rose in autoimmune disease patients after herpes zoster
MDedge Rheumatology
Jury still out on cannabinoid therapy for rheumatic diseases
MDedge Rheumatology
VIDEO: Mortality gap is closing between rheumatoid arthritis patients, general population
MDedge Rheumatology
VIDEO: Cardiovascular deaths declining in rheumatoid arthritis patients
MDedge Rheumatology